Notice of Intent to Award a Sole Source Commercial Simplified Acquisition Procedures (SAP) Contract for Development of a Human Neural Network Formation New Approach Method for the Evaluation of Potential Developmental Neurotoxicity
Summary
The FDA intends to award a sole source contract to Cyprotex US, LLC for development of a Human Neural Network Formation New Approach Method to evaluate potential developmental neurotoxicity. This effort focuses on creating a specialized assay that uses microelectrode array technology to assess neural toxicity, representing an advanced biotechnology approach to safety testing.